logo
menu
배경이미지
01About us
Spin offHistoryCollaborationCILoacation
02Platforms
Ocular ImplantsMicroarray Patches
03Pipelines
SMO SeriesSMM SeriesSMZ Series
04Facilities
SMO LineSMM LineSites
05Business
Business ModelCDMO Business
06News
NoticeIRPR
07Contact us
call@sminnovation.com
Home    >    About us    >    HistoryHistory
History Post Spinoff
Ocular Implants
Ocular Implants
MicroArray Patches
MicroArray Patches (MAP)
2017
  • ATC (Advanced Technology Center) project execution (Eye Disease Treatment R&D Center; 2014.6~2019.4)
2017-left-0
  • Teriparatide MAP R&D collaboration
2017-right-0
2018
  • Technical support for ocular implant platform development
2018-left-0
  • Teriparatide MAP co-development initiative
2018-right-0
2019
  • Collaboration on ocular implant injection container development
  • Collaboration on ocular implant automation equipment development
2019-left-0
2019-left-1
  • Teriparatide MAP efficacy evaluation collaboration
2019-right-0
2020
  • Selected for government-commissioned project (Implant injection container development)
2020-left-0
  • Teriparatide MAP clinical evaluation collaboration
2020-right-0
2021
  • Selected for government-commissioned project (Automated insertion equipment development)
2021-left-0
  • Selected for Bio-industry Core Technology Development (Teriparatide MAP development)
2021-right-0
2022
  • Selected for government-commissioned project (Laser cutting equipment development)
2022-left-0
  • Teriparatide MAP technology transfer agreement
2022-right-0
History Post Spinoff
2022
  • 09Established SM Innovation Co., Ltd.
  • 11Venture company certification (Venture investment type, No. 20221130010033)
2023
  • 01Recognition of corporate research institute (Korea Industrial Technology Promotion Association, No. 2023110127)
  • 07Selected for National New Drug Development Project (AMD sustained-release ocular implant development, participating company)
2024
  • 01Selected for enterprise order-type ocular implant production base technology development project (Korea Institute of Industrial Technology)
  • 03KEIT project selected (Innovative convergence bio-medical product technology development for obesity treatment, participating company)
  • 07SMZ1 Korea supply and sales agreement signed (Hallym Eye Health)
  • 09SMZ1 Korea Phase 3 clinical trial approved
2025
  • 06SMO-IVT1 Korea supply and sales agreement signed (Hallym Eye Health)
  • 08Scale-up TIPS R&D project selected (Ophthalmic special formulation intravitreal implant development platform)
  • 10SMO-IVT1 Korea Phase 3 clinical trial approved
2026
  • 02SMO-IVT1 license agreement signed (STADA, Germany)
footer-logo
CEO : Jinha Park
Company : SANGMYUNG innovation Co., Ltd.
T : +82 2 3489 6100
Head Office : 2-27, Yeongmun-ro, Cheoin-gu, Yongin-si, Gyeonggi-do, Republic of Korea
Branch Office : 42, Seocho-daero 52-gil, Seocho-gu, Seoul, Republic of Korea
Privacy PolicyCopyright © SANGMYUNG innovation